VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMW 2021 | Long-term disease-free survival in myeloma

Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, and Heinz Ludwig, MD, of the Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, talk on the latest developments in the field of multiple myeloma. Prof. Einsele discusses immunological strategies for myeloma treatment, such as antibody-drug conjugates, monoclonal antibodies and bispecific antibodies. Prof. Einsele also comments on the use of cellular therapies. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

Disclosures

Heinz Ludwig, MD, has received research funding from Amgen and Takeda; and has received speaker’s honoraria and has participated in advisory boards for Amgen, Takeda, Sanofi, Janssen, Celgene-BMS and Seattle Genetics.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter